The 38 references in paper A. Fonyakin V., L. Geraskina A., А. Фонякин В., Л. Гераскина А. (2017) “СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ ОБ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ ПРИ НЕКАРДИОЭМБОЛИЧЕСКОМ ИНСУЛЬТЕ // CURRENT VIEWS ON ANTITHROMBOTIC THERAPY IN NON-CARDIOEMBOLIC STROKE” / spz:neicon:aterotromboz:y:2017:i:1:p:123-133

1
Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke,
(check this in PDF content)
2
14, 45: 2160-2236. 2. Суслина З.А., Фонякин А.В., Кузнецов А.Л. Кардиоэмболический инсульт: источники эмболии и пути профилактики. Атмосфера. Новости кардиологии, 2004, 2: 13-16.
(check this in PDF content)
3
Гераскина Л.А., Фонякин А.В., Суслина З.А. Артериальная гипертония и гетерогенность ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. Инсульт. Приложение, 2003, 9: 138.
(check this in PDF content)
4
Суслина З.А., Фонякин А.В., Гераскина Л.А., Шандалин В.А. Кардионеврология. Справочное руководство с обзором клинических исследований. Под редакцией З.А. Суслиной и А.В. Фонякина М., 2011.
(check this in PDF content)
5
Olsson JE, Brechter C, Backlund H et al. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke,1980, 11: 4–9.
(check this in PDF content)
6
The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol, 1997, 42: 857–865.
(check this in PDF content)
7
Chimowitz MI, Lynn MJ, Howlett-Smith H et al, for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med, 2005, 352: 1305–1316.
(check this in PDF content)
8
The ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol, 2007, 6: 115–124.
(check this in PDF content)
9
The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol,1997, 42: 857–865.
(check this in PDF content)
10
Schryver EL, Algra A, Kappelle LJ et al. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev,2012, 9: CD001342.
(check this in PDF content)
11
Antithrombotic Tralists` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ,2002, 324: 71-86.
(check this in PDF content)
12
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of Patients. BMJ,1994, 308: 81–106.
(check this in PDF content)
13
He J, Whelton P, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA,1998, 280: 1930–1935.
(check this in PDF content)
14
Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2 (ESPS2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci, 1996, 143: 1-13.
(check this in PDF content)
15
Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidin Study (CATS) in thromboembolic stroke. Lancet,1989, 1: 1215-1220.
(check this in PDF content)
16
Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidin Aspirin Stroke Study Group. N Engl J Med, 1989, 321: 501-507.
(check this in PDF content)
17
Gorelick PB, Richardson D, Kelly M et al, for the African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA,2003, 289: 2947-2957.
(check this in PDF content)
18
CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet,1996, 348: 1329-1339.
(check this in PDF content)
19
Танашян М.М., Умарова Р.М., Гераскина Л.А., Фонякин А.В. Гемангиокорректорная эффективность Плавикса у больных с церебральной ишемией. Нервные болезни,2005, 3: 2-7.
(check this in PDF content)
20
Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet,2004, 364: 331-337.
(check this in PDF content)
21
Bhatt DL, Fox KAA, Hacke W et al. CHARISMA investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354: 1706-1717.
(check this in PDF content)
22
Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol, 2007, 49: 1982-1988.
(check this in PDF content)
23
SPS3 Investigators, Benavente OR, Hart RG, McClure LA et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med, 2012, 367: 817-825.
(check this in PDF content)
24
Kennedy J, Ryckborst KJ, Eliasziw M et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol, 2007, 6: 961–969.
(check this in PDF content)
25
Zuo F-T, Liu H, Wu H-J. The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese Patients A randomized and controlled trail. Medicine,2017, 96: 1-6 (e5497).
(check this in PDF content)
26
Wang Y, Wang Y, Zhao X et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med, 2013, 369: 11-9.
(check this in PDF content)
27
Xie W, Zheng F, Zhong B, Song X. Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis. J Am Heart Assoc, 2015, 4: 2-15. e002259.
(check this in PDF content)
28
Koziol K, Van der Merwe V, Yakiwchuk E, Kosar L. Dual antiplatelet therapy for secondary stroke prevention Use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke. Canadian Family Physician,2016, 62: 640-645.
(check this in PDF content)
29
Ge F, Lin H, Liu Y, Li M et al. Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol, 2016, 23: 1051-1057.
(check this in PDF content)
30
The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet,1987, 2: 1351–1354.
(check this in PDF content)
31
The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet,2006, 367: 1665-1673.
(check this in PDF content)
32
Diener HC, Sacco RL, Yusuf S, Steering Committee of PROFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two Antithrombotic regimen (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with stroke. The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). Cerebrovasc Dis, 2007, 23: 368–380.
(check this in PDF content)
33
Costa J, Ferro JM, Matias-Guiu J et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke,2006, 37, 2193-2195.
(check this in PDF content)
34
Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol, 2008, 7: 494-499.
(check this in PDF content)
35
Shinohara Y, Katayama Y, Uchiyama S et al, CSPS 2 Group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, doubleblind, randomised non-inferiority trial. Lancet Neurol, 2010, 9: 959–968.
(check this in PDF content)
36
Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS). Stroke,2008, 39: 1827-1833.
(check this in PDF content)
37
Johnston SC, Amarenco P, Albers GW et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med, 2016, 375: 35-43.
(check this in PDF content)
38
Amarenco P, Albers GW, Denison H et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet
(check this in PDF content)